Phathom Pharmaceuticals (PHAT) Gross Profit (2023 - 2026)

Phathom Pharmaceuticals (PHAT) has 4 years of Gross Profit data on file, last reported at $46.3 million in Q1 2026.

• Gross Profit for Q1 2026 came in at $46.3 million, up 86.75% year-over-year; the trailing twelve-month figure through Mar 2026 was $174.0 million (up 146.53% YoY), and the FY2025 annual result was $152.5 million, up 222.58% from the prior year.
• Gross Profit fell to $46.3 million in Q1 2026 per PHAT's latest filing, from $49.9 million in the prior quarter.
• Over five years, Gross Profit peaked at $49.9 million in Q4 2025 and troughed at $515000.0 in Q4 2023.
• A 4-year average of $24.7 million and a median of $25.3 million in 2024 frame the typical range for Gross Profit.
• The sharpest annual moves came in 2024 and 2026: Gross Profit surged 4919.22% in 2024, then surged 86.75% in 2026.
• A 4-year view of Gross Profit shows it stood at $515000.0 in 2023, then surged by 4919.22% to $25.8 million in 2024, then soared by 93.18% to $49.9 million in 2025, then retreated by 7.27% to $46.3 million in 2026.
• Business Quant data shows PHAT's Gross Profit at $46.3 million in Q1 2026, $49.9 million in Q4 2025, and $43.3 million in Q3 2025.